Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Basilea Pharmaceutica AG is a biopharmaceutical company headquartered in Basel, Switzerland. The company focuses on the research, development, and commercialization of innovative medicines, primarily in the areas of infectious diseases and oncology. Some of its key products include antifungal and antibiotic treatments like Cresemba and Zevtera, which address significant medical needs in their respective markets. Basilea was founded as a spin-off from Roche in 2000, reflecting its strong roots in pharmaceutical research. The company's strategic positioning capitalizes on its expertise in addressing drug-resistant bacterial infections and rare fungal infections, providing solutions where few alternatives exist. Basilea operates on a global scale, collaborating with international partners to expand its research and market reach.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Basilea Pharmaceutica AGEli Lilly
Last price
€70.15$1,164.17
Currency
EUR
USD
€879M$1T
16.5238.37
€4.30$29.79
0.430.50
0$6.69
00.61%
Sector
HealthHealth
Employees
20050,000
Ticker
€BSLN$LLY
Primary listing
XGATNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €BSLN or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.